Skip to main content
. 2022 Mar 17;6:16. doi: 10.1038/s41698-022-00260-0

Fig. 2. Focused inhibitor library screening revealed that GSK3 inhibitors specifically suppressed lorlatinib intermediate resistant cell viability.

Fig. 2

Difference in drug sensitivity to each drug between JFCR-028-3 lorlatinib intermediate resistant cells and JFCR-028-3 parental cells. The difference of drug sensitivity was calculated from the cell viability of JFCR-028-3 lorlatinib intermediate resistant cells and JFCR-028-3 parental cells in each drug (n = 2). Relative cell viability was calculated from each value divided by the DMSO control.